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Experimental and clinical data support a growth inhibitory
role for HER4 in breast cancer. Clinically HER4 expres-
sion is extinguished during breast tumorigenesis supporting
a tumor suppressor function for HER4, however, a molecular
mechanism to explain the selective loss of HER4 expression
has remained elusive. Epigenetic mechanisms, for example,
aberrant gene promoter hypermethylation, have been shown
to ablate tumor suppressor gene expression in breast
carcinomas. We identiﬁed a CpG island within the HER4
promoter and show by pyrosequencing of bisulﬁte-treated
DNA an inverse correlation between HER4 expression and
the extent of promoter methylation. Treatment of the HER4-
negative BT20 cell line with the DNA demethylating agent
5-aza-20-deoxycytidine (DAC)-enhanced HER4 expression,
conﬁrming a role for DNA methylation in suppressed HER4
expression. DAC treatment to reactive HER4 expression in
combination with the HER4 ligand heregulin-b1 (HRG)
resulted in apoptosis of BT20 cells providing a novel thera-
peutic strategy for triple-negative tumors. The BT20 cells
were rescued from apoptosis when preincubated with HER4
small interfering RNA, thereby conﬁrming a role for HER4
in DAC/HRG-induced apoptosis. We veriﬁed HER4 promo-
ter methylation in primary breast carcinomas and detected a
signiﬁcant increase in HER4 promoter methylation in HER4-
negative breast tumors (Po0.001). Furthermore, increased
levels of HER4 promoter methylation were signiﬁcantly
associated with worse patient prognosis (P¼0.0234). Taken
together, our data support a tumor suppressor function for
HER4, which is epigenetically suppressed in breast tumors
through promoter hypermethylation.
Oncogene (2010) 29, 5214–5219; doi:10.1038/onc.2010.271;
published online 5 July 2010
Keywords: breast cancer; EGFR-family; epigenetics;
apoptosis; heregulin
Introduction
The HER4/ERBB4 receptor tyrosine kinase belongs to
the epidermal growth factor receptor-family of potent
breast oncogenes. However, HER4 expression in breast
carcinomas independently predicts improved patient
survival (Thor et al., 2009) while inversely correlating
with tumor grade, metastasis and disease recurrence
(Sundvall et al., 2008; Kreike et al., 2009). Furthermore,
when examined in the context of the recently deﬁned
molecular subtypes of breast tumors, HER4 expression
is most prevalent in the luminal subtypes associated with
the best overall patient survival while HER4 is rarely
expressed in the HER2-positive or triple-negative tumor
subtypes with the worst patient prognosis (Perou et al.,
2000; Sorlie et al., 2001; Hoadley et al., 2007). When
expressed in tumor subtypes associated with poor
prognosis, HER4 predicts improved patient response
to multiple therapeutic interventions (Naresh et al.,
2008; Sassen et al., 2009).
Experimental models provide mechanistic support for
these clinical observations and further suggest that
HER4 has potent anti-tumor activity in the breast.
For example, HER4 activation inhibits proliferation of
multiple breast tumor cell lines by promoting differ-
entiation and/or apoptosis (Naresh et al., 2006; Mur-
aoka-Cook et al., 2006b; Jones, 2008). In preclinical
xenograft models, HER4 apoptotic activity is essential
for tamoxifen-mediated tumor cell killing and patients
with tumor expression of HER4 respond to tamoxifen
therapy with no failures after 14 years (Naresh et al.,
2008). Ligand-activated HER4 has also been shown to
cooperate with BRCA1 to induce a G2/M delay during
breast tumor cell cycle progression (Muraoka-Cook
et al., 2006a). Although under some experimental
conditions HER4 has also been shown to promote
breast tumor cell proliferation (Zhu et al., 2006; Jones,
2008; Muraoka-Cook et al., 2009) these results require
clinical veriﬁcation.
Although loss of HER4 expression during breast
tumor progression to higher grade and metastatic
carcinomas is supported clinically, (Sundvall et al.,
2008) a mechanism for the selective loss of HER4
activity during breast tumorigenesis remains elusive.
Independent laboratories have identiﬁed somatic muta-
tions, which potentially attenuate HER4 activity (Soung
et al., 2006; Rokavec et al., 2007; Tvorogov et al., 2008).
These mutations, however, were only observed in a
small percentage (1–5%) of breast tumors and therefore
cannot account for the absence of HER4 expression
observed in 32% of all breast tumors (Thor et al., 2009)
and 90% of the most aggressive breast carcinomas
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www.nature.com/onc(Hoadley et al., 2007). Epigenetic mechanisms of gene
suppression are commonly observed in breast tumors
and one epigenetic event involving hypermethylation of
gene promoter CpG sites has been shown to abolish
expression of multiple tumor suppressors in the breast
including BRCA1 (Esteller, 2007). In this study, we
show that hypermethylation of a CpG island in the
HER4 promoter is associated with suppressed HER4
expression in breast tumors. Reactivation of HER4
expression results in tumor cell apoptosis supporting a
tumor suppressor function for HER4 in the breast.
Results and discussion
The HER4 promoter is hypermethylated
in HER4-negative breast tumor cell lines
In breast cancer, aberrant hypermethylation of CpG
islands within gene promoters is a common mecha-
nism of tumor suppressor inactivation (Esteller, 2007).
To determine if promoter hypermethylation regulates
HER4 expression in breast tumor cells, we ﬁrst analyzed
the HER4 gene for the presence of CpG islands using
UCSC Genome Bioinformatics. One CpG island was
identiﬁed positioned at  580 to þ1107 relative to the
HER4 transcriptional start site (Figure 1). Extension
of the CpG island into the ﬁrst exon–intron sequence is
potentially signiﬁcant because these CpG sites can affect
chromatin structure and gene regulatory transcription
factor binding (Strathdee et al., 2004). In addition,
exon–intron CpG sites may serve as ‘seed’ sequences for
upstream CpG methylation and gene silencing (Nguyen
et al., 2001). An analysis of HER4 promoter methyla-
tion by pyrosequencing of bisulﬁte-treated DNA iso-
lated from multiple breast tumor cell lines revealed a
striking inverse correlation between HER4 expression
and the extent of promoter methylation (Figures 2a–c).
To determine the methylation status of each CpG site
between  274 and þ43, we analyzed DNA from three
representative cell lines by direct bisulﬁte DNA sequen-
cing. For each cell line, multiple DNA strand copies
were analyzed by cloning the bisulﬁte PCR product
and sequencing at least 10 individual clones. None of the
42 CpG sites was methylated in the 11 individual
DNA isolates analyzed from HER4-expressing T47D
cells (Figure 2d). In concordance with decreasing levels
of HER4 expression, the extent of CpG site methylation
increased within MDAMB468, and was even greater
within BT20 cells (Figure 2d). Taken together, our data
suggest that HER4 expression is suppressed in breast
tumor cells through hypermethylation of multiple CpG
sites within the HER4 promoter.
Reactivated expression of HER4 promotes breast tumor
cell apoptosis
We have previously shown that HER4 functions as a
pro-apoptotic BH3-only protein of the BCL-2 family
and when ligand-activated HER4 induces apoptosis of
multiple tumor cell lines (Vidal et al., 2005; Naresh
et al., 2006). This apoptotic activity may not be unique
to HER4. For example, HER2, another epidermal
growth factor receptor-family member, undergoes cas-
pase cleavage to generate a HER2 intracellular domain
with pro-apoptotic BH3-only protein activity (Strohecker
et al., 2008). Epigenetic silencing of HER4 expression
may provide a mechanism for breast tumor cells to evade
HER4-induced apoptosis. Indeed, evasion of apoptosis
is one of the obligate hallmarks of tumorigenesis
(Hanahan and Weinberg, 2000). To determine if reacti-
vated HER4 expression can suppress tumorigenesis, we
reactivated HER4 expression by treating BT20 cells with
the demethylating agent 5-aza-20-deoxycytidine (DAC).
This cell line had the highest levels of HER4 promoter
methylation and resembles triple-negative breast tumors.
Patients with advanced triple-negative breast tumors have
extremely poor prognosis and because these tumors lack
targetable molecular markers therapeutic options for
these patients are limited to cytotoxic therapy. DAC
treatment of BT20 cells resulted in increased HER4
expression detectable at both the RNA and protein levels
(Figures 3a and c). These results further conﬁrm that
HER4 expression is suppressed in these breast tumor cell
lines through a reversible DNA methylation mechanism.
Figure 1 Identiﬁcation of an ERBB4 CpG island. A CpG island was identiﬁed within the ERBB4 locus between  580 and þ1107
relative to the transcriptional start site (TSS) using UCSC Genome Bioinformatics software. The lower portion shows a schematic of
the CpG island between  580 and þ211 relative to the TSS with CpG sites indicated by vertical black lines. Regions ampliﬁed by PCR
for BST sequencing and pyrosequencing are indicated.
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stimulation of endogenous HER4 results in apoptosis
of breast tumor cell lines (Naresh et al., 2006),
however, non-malignant cells appear to be resistant to
HER4 apoptotic activity (Vidal et al., 2007). In non-
transformed cells, the HER4 intracellular domain and
BH3-only protein, 4ICD, is sequestered to the nucleus in
which it cooperates with STAT5A to regutle gene
expression (Long et al., 2003; Williams et al., 2004).
To determine if the apoptotic activity of reactivated
HER4 can be induced in the BT20 cell line, we combined
DAC treatment with HRG stimulation of the BT20 cell
line. Treatment of BT20 cells with increasing concentra-
tions of DAC resulted in an insigniﬁcant increase in cell
death. Concurrent treatment with HRG, however,
resulted in dramatic cell killing after 48h of treatment
(Figure 3b). Although DAC treatment typically affects
expression of o1% of the human transcriptome, we
cannot rule out the possibility that the DAC/HRG
combination induces apoptosis independent of HER4.
To conﬁrm a role for reactivated HER4 in DAC/HRG-
mediated cell killing, we suppressed reactivated HER4
expression by concurrent HER4 RNA interference
treatment. The DAC/HRG combination failed to
promote signiﬁcant levels of tumor cell apoptosis when
HER4 expression was suppressed thereby demons-
trating an obligate role for HER4 expression in DAC/
HRG-induced apoptosis (Figures 3b and c). Taken
together, these data suggest that breast tumor cells
selectively suppress HER4 expression through promoter
hypermethylation to evade the cell-killing activity of
HER4. Interestingly, the HRG gene is also epigenetically
silenced in breast carcinomas (Chua et al., 2009;
Fernandez et al., 2010). Our observation that HRG
stimulation of reactivated HER4 results in breast tumor
apoptosis serves as an important proof-of-principle for
Figure 2 The HER4 promoter is hypermethylated in breast tumor cells. (a) Relative HER4 expression determined by quantitative
reverse transcriptase (qRT)–PCR with each cell line normalized to MCF-7 cells. Total RNA was isolated from cell lines using Trizol
Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturers’ instructions. Superscript III (Invitrogen
Life Technologies) was used to generate complementary DNA and HER4 expression was determined using ERBB4 TaqMan PCR
primers and probe (assay ID Hs00171783_m1) with TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA)
in a ABI Prism 7000 (Applied Biosystems). HER4 expression was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(assay ID Hs99999905_m1) and the 2
 DDCt method was used to calculate relative HER4 expression levels. (b) The CpG sites between
 274 and  26 were analyzed by pyrosequencing and the mean methylation was determined. Data represent the mean and standard
error of three independent DNA puriﬁcations. For pyrosequencing, the region of the ERBB4 CpG island between  130 and  62 (CpG
sites 24–38) was ampliﬁed from bisulﬁte-treated DNA using primers 50-GTTYGTTTTGGGAGTYGTTATAT-30 and biotinylated
50-ATCCAAATAACATATCCCCCTTT-30. The sequencing primer 50-GTTTTGGGAGTYGTTATA-30 was used for pyrosequencing
at EpigenDx (Worcester, MA, USA). (c) Simple regression plot with 95% conﬁdence interval in which each point represents one breast
tumor cell line. (d) Bisulﬁte sequencing analysis of HER4 CpG sites between  274 and þ43 relative to the transcriptional start site
(TSS) from 10 independent DNA clones for each cell line. Open boxes indicate unmethylated CpG sites and closed boxes indicate
methylated CpG sites. DNA was isolated from cultured cells and bisulﬁte treated using EZ DNA Methylation Gold Kit
(Zymo Research, Orange, CA, USA) according to the manufacturer’s instructions. A region of the ERBB4 CpG island between  274
and þ43 relative to the transcriptional start site (TSS) was PCR ampliﬁed using primers designed for bisulﬁte-modiﬁed DNA
(50-AGTGAGAGAGAGAGAAAGTGAGGAG-30 and 50-CACCCAAACCCAAAATCCTA-30) and PCR products were cloned into
TOPO TA Cloning Kit (Invitrogen Life Technologies). DNA was puriﬁed from 10 or 11 clones for each cell line and sequenced.
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HER4 promoter hypermethylation in primary breast
tumors is associated with decreased patient survival
We next determined the levels of HER4 promoter
methylation in a cohort of 25 primary breast tumors
previously analyzed for HER4 expression by immuno-
histochemistry (Thor et al., 2009). In the 13 HER4-
positive tumors, the levels of HER4 promoter methylation
ranged from 0.5 to 4.3% with a mean of 2.4% (Figures 4a
and b). HER4 promoter methylation in 12 HER4-
negative tumors had a signiﬁcantly higher mean of
11.5% (Figures 4a and b; Po0.001). These results
implicate HER4 promoter hypermethylation as an
important mechanism promoting suppression of HER4
expression in primary breast carcinomas. We expanded
our cohort to 35 patients and determined the effect of
HER4 promoter methylation on patient survival using
a cutoff of 3% methylation. We found that patients
whose tumors had HER4 promoter methylation levels
X3% had signiﬁcantly shorter disease-speciﬁc survival
(Figure 4c; P¼0.0234). Strikingly, a failure in the low
HER4 methylation population was not observed until
nearly 15 years after diagnosis. Taken together, our
results provide an important clinical correlate implicat-
ing HER4 promoter hypermethylation as an epigenetic
event promoting breast tumor progression and reduced
patient survival.
In summary, we have identiﬁed a molecular mechan-
ism to explain the selective suppression of HER4
expression observed clinically during breast tumorigen-
esis. Accordingly, we show that extinguished HER4
expression is associated with promoter hypermethyla-
tion in both breast tumor cell lines and primary
carcinomas. Furthermore, breast tumor HER4 promo-
ter methylation 43% was signiﬁcantly associated with
poor patient prognosis. In fact, all patients in our cohort
with tumor HER4 promoter methylation o3% survived
for at least 15 years after diagnosis. Signiﬁcantly,
reactivation of epigenetically silenced HER4 followed
by HRG stimulation results in tumor cell apoptosis
supporting a tumor suppressor function for HER4 in
breast cancer. Our results, therefore, provide a proof-of-
principle therapeutic rationale for marshaling HER4
Figure 3 Reactivation of HER4 expression results in tumor cell apoptosis. (a) The BT20 breast tumor cell line was treated with the
indicated amount of DAC for 48h. HER4 expression after DAC treatment relative to dimethylsulphoxide (DMSO) vehicle control was
determined by quantitative reverse transcriptase (qRT)–PCR as described in Figure 2a. (b) BT20 cells were treated with the indicated
amount of DAC in combination with 50ng/ml of HRG and analyzed for apoptosis after 48h. The percentage of cells undergoing
apoptosis was determined using a combination of 40,6-diamidoino-2-phenylindole (DAPI) staining for condensed chromatin and
TUNEL assay as described elsewhere (Naresh et al., 2008). In some experiments, HER4 expression was suppressed using erbB-4/HER-
4 small interfering RNA (siRNA) SMARTpool or a nonspeciﬁc negative control pool (Upstate Biotechnology, Lake Placid, NY,
USA) exactly as described elsewhere (Naresh et al., 2008). BT20 cells were pretreated with HER4 siRNA 24h before DAC and HRG
treatments. Results represent the mean and standard error of at least three independent experiments. (c) Western blot analysis of HER4
expression in BT20 cells treated with DMSO or DAC in the presence or absence of control RNA interference (RNAi) or HER4 RNAi.
Treatments were performed as described in panel (b). Total cell lysates were prepared and analyzed by western blot exactly as described
elsewhere (Jones et al., 1999). Primary antibodies used for western blot analysis included ErbB4 E200 (Abcam, Cambridge, MA, USA)
and a-tubulin #05829 (Upstate Biotechnology). Secondary antibodies were IRDye 680 goat anti-rabbit (Li-Cor Biosciences, Lincoln, NE,
USA) or IRDye 800 goat anti-mouse (Li-Cor Biosciences) detected using an Odyssey Infrared Imaging System (Li-Cor Biosciences).
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